Cargando…

Fatal drug-induced immune hemolytic anemia due to cefotetan; A case study

A case is described here of drug-induced immune hemolytic anemia (DIIHA) due to cefotetan administered to a post-partum woman who received the drug for infection prophylaxis at the time of caesarean section. Renewed fatal hemolysis occurred when the drug was given a second time 12 days after the fir...

Descripción completa

Detalles Bibliográficos
Autor principal: Perkins, Jim
Formato: Texto
Lenguaje:English
Publicado: Medknow Publications 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2798759/
https://www.ncbi.nlm.nih.gov/pubmed/20041074
http://dx.doi.org/10.4103/0973-6247.39507
_version_ 1782175736484855808
author Perkins, Jim
author_facet Perkins, Jim
author_sort Perkins, Jim
collection PubMed
description A case is described here of drug-induced immune hemolytic anemia (DIIHA) due to cefotetan administered to a post-partum woman who received the drug for infection prophylaxis at the time of caesarean section. Renewed fatal hemolysis occurred when the drug was given a second time 12 days after the first dose. The initial immunohematologic findings included a positive direct antiglobulin test (DAT) due to IgG and complement coating of the patient’s RBCs as well as an eluate that did not react with RBCs in the absence of drug. The antibody was drug-dependent, reacting with both drug-coated RBCs as well as when the drug was added to a mixture of her serum and donor RBCs. Cefotetan has been a common cause of this uncommon problem. The clinical features of cefotetan DIIHA, classification of drug-induced antibodies, and the differential diagnosis of a positive DAT are briefly discussed.
format Text
id pubmed-2798759
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Medknow Publications
record_format MEDLINE/PubMed
spelling pubmed-27987592009-12-29 Fatal drug-induced immune hemolytic anemia due to cefotetan; A case study Perkins, Jim Asian J Transfus Sci Case Report A case is described here of drug-induced immune hemolytic anemia (DIIHA) due to cefotetan administered to a post-partum woman who received the drug for infection prophylaxis at the time of caesarean section. Renewed fatal hemolysis occurred when the drug was given a second time 12 days after the first dose. The initial immunohematologic findings included a positive direct antiglobulin test (DAT) due to IgG and complement coating of the patient’s RBCs as well as an eluate that did not react with RBCs in the absence of drug. The antibody was drug-dependent, reacting with both drug-coated RBCs as well as when the drug was added to a mixture of her serum and donor RBCs. Cefotetan has been a common cause of this uncommon problem. The clinical features of cefotetan DIIHA, classification of drug-induced antibodies, and the differential diagnosis of a positive DAT are briefly discussed. Medknow Publications 2008-01 /pmc/articles/PMC2798759/ /pubmed/20041074 http://dx.doi.org/10.4103/0973-6247.39507 Text en © Asian Journal of Transfusion Science http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Perkins, Jim
Fatal drug-induced immune hemolytic anemia due to cefotetan; A case study
title Fatal drug-induced immune hemolytic anemia due to cefotetan; A case study
title_full Fatal drug-induced immune hemolytic anemia due to cefotetan; A case study
title_fullStr Fatal drug-induced immune hemolytic anemia due to cefotetan; A case study
title_full_unstemmed Fatal drug-induced immune hemolytic anemia due to cefotetan; A case study
title_short Fatal drug-induced immune hemolytic anemia due to cefotetan; A case study
title_sort fatal drug-induced immune hemolytic anemia due to cefotetan; a case study
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2798759/
https://www.ncbi.nlm.nih.gov/pubmed/20041074
http://dx.doi.org/10.4103/0973-6247.39507
work_keys_str_mv AT perkinsjim fataldruginducedimmunehemolyticanemiaduetocefotetanacasestudy